US20060188516A1 - Chlamydia trachomatis antigens - Google Patents

Chlamydia trachomatis antigens Download PDF

Info

Publication number
US20060188516A1
US20060188516A1 US11/272,051 US27205105A US2006188516A1 US 20060188516 A1 US20060188516 A1 US 20060188516A1 US 27205105 A US27205105 A US 27205105A US 2006188516 A1 US2006188516 A1 US 2006188516A1
Authority
US
United States
Prior art keywords
protein
chlamydia
proteins
spot
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/272,051
Other languages
English (en)
Inventor
Giulio Ratti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to US11/272,051 priority Critical patent/US20060188516A1/en
Publication of US20060188516A1 publication Critical patent/US20060188516A1/en
Priority to US12/586,601 priority patent/US8114401B2/en
Priority to US13/344,490 priority patent/US20130156775A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/125—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Chlamydiales (O)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56927—Chlamydia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/295—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Chlamydiales (o)

Definitions

  • This invention relates to antigenic proteins from Chlamydia trachomatis.
  • it relates to antigens which are recognised by antibodies from chronically infected or convalescent patient sera.
  • Chlamydia are obligate intracellular parasites of eukaryotic cells which are responsible for endemic sexually transmitted infections, trachoma, infectious pneumonitis, and various other disease syndromes. They occupy an exclusive eubacterial phylogenic branch, having no close relationship to any other known organisms—they are classified in their own order ( Chlamydiales ) which contains a single family ( Chlamydiaceae ) which in turn contains a single genus ( Chlamydia ).
  • Chlamydiales which contains a single family
  • Chlamydiaceae Chlamydiaceae
  • Chlamydia Four chlamydial species are currently known— C.trachomatis, C.pneumoniae, C.pecorum and C.psittaci [eg. see reference 1].
  • a genome sequence of C.trachomatis has recently been published [2].
  • serovars The human serovariants (“serovars”) of C.trachomatis are divided into two biovariants (“biovars”). Serovars A-K elicit epithelial infections primarily in the ocular tissue (A-C) or urogenital tract (D-K). Serovars L1, L2 and L3 are the agents of invasive lymphogranuloma venereum (LGV).
  • serovars A-K elicit epithelial infections primarily in the ocular tissue (A-C) or urogenital tract (D-K).
  • Serovars L1, L2 and L3 are the agents of invasive lymphogranuloma venereum (LGV).
  • chlamydial infection itself causes disease, it is thought that, in some patients, the severity of symptoms is due, in fact, to an aberrant host immune response. Failure to clear the infection results in persistent immune stimulation and, rather than helping the host, this results in chronic infection with severe consequences, including sterility and blindness [3].
  • vaccines are useful (a) for immunisation against chlamydial infection or against chlamydia -induced disease (prophylactic vaccination) or (b) for the eradication of an established chronic chlamydial infection (therapeutic vaccination). Being an intracellular parasite, however, the bacterium can generally evade antibody-mediated immune responses.
  • antigenic proteins have been described for C.trachomatis, and the cell surface in particular has been the target of detailed research [eg. 1,4]. These include, for instance, pgp3 [5,6,71, MOMP [8], Hsp6O (GroEL) [9] and Hsp7O (DnaK-like) [10]. Not all of these have proved to be effective vaccines, however, and it is an object of the invention to identify chlamydial antigens which elicit an immune response during natural infection, in order to provide antigens and immunogens suitable for use in vaccine development.
  • the invention is based on the identification of proteins encoded by Chlamydia trachomatis which are immunogenic in man as a consequence of infection.
  • the invention provides a C. trachomatis protein having the MW and pI characteristics of protein 5, 6, 7, 8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, as set out in Table II on page 15.
  • proteins having, in the L2 strain of C.trachomatis, an N-terminal amino acid sequence disclosed in Table III on page 16.
  • the invention also provides proteins having sequence identity to these C. trachomatis proteins.
  • the degree of identity is preferably greater than 50% (eg. 65%, 80%, 90%, 95%, 98%, 99% or more).
  • homologous proteins include mutants, allelic variants, serovariants, and biovariants.
  • 50% identity or more between two proteins is considered to be an indication of functional equivalence.
  • the invention further provides proteins comprising fragments of the C.trachomatis proteins of the invention.
  • the fragments should comprise at least n consecutive amino acids from the proteins and, depending on the particular protein, n is 7 or more (eg. 8, 10, 12, 14, 16, 18, 20, 50, 100 or more).
  • n is 7 or more (eg. 8, 10, 12, 14, 16, 18, 20, 50, 100 or more).
  • the fragments comprise an epitope from the protein.
  • the proteins of the invention can, of course, be prepared by various means (eg. recombinant expression, purification from cell culture, chemical synthesis etc.) and in various forms (eg. native, fusions etc.). They are preferably prepared in substantially isolated or purified form (ie. substantially free from other C.trachomatis or host cell proteins)
  • the invention provides antibodies which bind to these proteins. These may be polyclonal or monoclonal and may be produced by any suitable means.
  • the invention provides nucleic acid encoding the proteins and protein fragments of the invention. Nucleic acid having sequence identity to this nucleic acid is also provided. Depending on the particular nucleic acid, the degree of identity is preferably greater than 50% (eg. 65%, 80%, 90%, 95%. 98%, 99% or more).
  • nucleic acid which can hybridise to this nucleic acid, preferably under “high stringency” conditions (eg. 65° C. in a 0.1 ⁇ SSC, 0.5% SDS solution).
  • fragments of this nucleic acid are also provided.
  • the fragments should comprise at least n consecutive nucleotides from the sequences and, depending on the particular sequence, n is 10 or more (eg. 12, 14, 15, 18,20,25,30,35.40 or more).
  • nucleic acid comprising sequences complementary to those described above (eg. for antisense or probing purposes).
  • Nucleic acid according to the invention can, of course, be prepared in many ways (eg. by chemical synthesis, from genomic or cDNA libraries, from the organism itself etc.) and can take various forms (eg. single stranded, double stranded, vectors, probes etc.).
  • nucleic acid includes DNA and RNA, and also their analogues, such as those containing modified backbones, and also peptide nucleic acids (PNA) etc.
  • PNA peptide nucleic acids
  • the invention provides vectors comprising nucleic acid of the invention (eg. expression vectors) and host cells transformed with such vectors.
  • nucleic acid of the invention eg. expression vectors
  • compositions comprising protein, antibody, and/or nucleic acid according to the invention.
  • These compositions may be suitable as immunogenic compositions (including vaccines), for instance, or as diagnostic reagents.
  • the invention also provides nucleic acid, protein, or antibody according to the invention for use as medicaments (eg. as vaccines) or as diagnostic reagents.
  • the invention provides protein 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, or 55 (as set out in Table II on page 15) for use as a chlamydial immunogen. Whilst it is believed that some of the proteins described in Table II may be known per se, they have not been disclosed as being immunogenic.
  • the invention also provides the use of nucleic acid, protein, or antibody according to the invention in the manufacture of (i) a medicament for treating or preventing infection due to Chlamydia; (ii) a diagnostic reagent for detecting the presence of Chlamydia or of antibodies raised against Chlamydia; and/or (iii) a reagent which can raise antibodies against Chlamydia.
  • the Chlamydia may be any species or strain, but is preferably C trachomatis.
  • the invention provides a protein of the 55 proteins of Table II for use in such manufacture.
  • the invention also provides a method of treating a patient, comprising administering to the patient a therapeutically effective amount of nucleic acid, protein, and/or antibody according to the invention.
  • the invention provides various processes.
  • a process for producing proteins of the invention comprising the step of culturing a host cell according to the invention under conditions which induce protein expression.
  • a process for producing protein or nucleic acid of the invention wherein the protein or nucleic acid is synthesised in part or in whole using chemical means.
  • a process for detecting nucleic acid of the invention comprising the steps of: (a) contacting a nucleic probe according to the invention with a biological sample under hybridising conditions to form duplexes: and (b) detecting said duplexes.
  • a process for detecting proteins of the invention comprising the steps of: (a) contacting an antibody according to the invention with a biological sample under conditions suitable for the formation of an antibody-antigen complexes; and (b) detecting said complexes.
  • the invention provides a process for detecting anti-chlamydial antibodies in a sample, comprising the steps of: (a) contacting a protein according to the invention with a biological sample under conditions suitable for the formation of an antibody-antigen complexes; and (b) detecting said complexes.
  • kits comprising reagents suitable for use in these processes.
  • a kit is provided comprising a nucleic probe according to the invention and means for detecting duplexes formed by the probe.
  • a kit is provided comprising an antibody according to the invention and means for detecting antibody-antigen complexes formed by the antibody.
  • a kit is provided comprising a protein according to the invention and means for detecting antibody-antigen complexes formed by the protein.
  • composition “comprising” encompasses “including” as well as “consisting” eg. a composition “comprising” X may consist exclusively of X or may include something additional to X, such as X+Y.
  • FIG. 1 shows the annotated reference 2D electrophoretic EB map, also indicating the positions of the immunoreactive protein spots, labelled 1-55. Groups of spots which appear to be an isolectric series of the same protein are encircled together and classified under the same identification number.
  • FIG. 2 shows typical immunoblots. The whole map area is shown. Major known immunogens are marked for easier comparison. For other spot identification, refer to FIG. 1 and table II.
  • Blot A is from PID patient JO05 (MIF titre 256), and has a serum dilution 1:5000.
  • Blot B is from patient J035 (MIF titre 64) affected by secondary sterility, and has a serum dilution 1:2500.
  • Blot C is similar to blot B, but is from patient J052.
  • Blot D is from PID patient JO31 (MIF titre 256), and gas a serum dilution 1:5000.
  • Sera (Table I) were obtained from women who had responded to a chlamydial infection of the genital tract.
  • the seventeen sera (A . . . Q) were obtained from 4 cases of lower genital tract infection and 13 laparoscopically-confirmed cases of PID (pelvic inflammatory disease), including 2 cases of secondary sterility. All sera were positive for a standard microimmunofluorescence test (MIF) with purified C.trachomatis L2 elementary bodies [11], and confirmed as C.trachomatis immune sera by an ELISA test with the plasmid-encoded pgp3 antigen [5].
  • MIF microimmunofluorescence test
  • a group of 10 seronegative control sera from healthy blood donors was tested by immunoblotting in the same way, and using the same dilutions as for patient sera, in order to exclude the occurrence of non-specific reactions.
  • Purified chlamydial cells were obtained as described in reference 12, by growing C.trachomatis strain L2/343/Bu in Vero cell cultures according to standard procedures, followed by two cycles of density gradient centrifugation [13].
  • the average protein concentration of the purified elementary body (EB) preparation was determined using a biuret assay. Aliquots (2 mg protein/nil) were stored in water at ⁇ 20° C. for subsequent electrophoretic analysis.
  • the cells used were mainly in the form of EBs—all known chlamydial antigens to date have been found in elementary bodies, rather than reticular bodies.
  • Chlamydial proteins were separated using high resolution 2D electrophoresis, performed using the immobiline/polyacrylamide system, essentially as described in references 14 and 15.
  • FIG. 1 shows the annotated reference EB map which was used to identify proteins on immunoblots. MW and pI coordinates for the reference map were calibrated by co-migration of the chlamydial proteins with human serum proteins acting as reference proteins. The isoelectric point values used for serum proteins were those described in reference 17.
  • the gels were electroblotted onto nitrocellulose membranes [18], and processed according to standard procedures, modified as described in reference 19. Briefly, before immunodetection, the membranes were stained in 0.2% (w/v)
  • Immunoreactive spots were detected by overnight incubation at room temperature with patient sera (1500-5000 ⁇ dilutions), followed by incubation with rabbit anti-human IgGs conjugated with peroxidase (Cappel, 7000 ⁇ dilution), and detection with a chemiluminescence based kit (Pharmacia Amersham Biotech).
  • spot signals on the immunoblot almost always corresponded to a spot on the silver stained gel.
  • immunoblot analysis detected protein spots which were not visible in the silver stained map. This shows that this technique has a superior sensitivity and should be taken into consideration as a valuable tool also for systematic proteomics studies.
  • the nitrocellulose blots were marked with a number of internal “anchor” spots using transient Ponceau Red staining. After incubation with the sera and detection of bound antibodies by chemiluminescence, the immunoblot images were matched to the reference map and spots were assigned the corresponding pI and MW coordinates (see Table II). When the position and shape of the spot (or isoelectric series of spots) coincided with a previously-identified EB antigen, an immune response against such antigen was recorded. In all other cases the immunoblot spot was identified by the MW and p 1 coordinates taken at the baricentre of the stained area (or the coordinate range, in the case of complex spot patterns). It will be appreciated that the MW and pI values are determined electrophoretically, and may have a potential average error of ⁇ 10%. The higher MW measurements will tend to be less accurate.
  • FIG. 2 Typical immunoblot results are shown in FIG. 2 .
  • This cluster is shown as spot 1 in FIG. 1 —all the spots labelled “1” were scored as a single antigen, but a number of accessory spots with lower MW and pI values which usually appear associated to OMP2 reactivity were separately scored, as their relationship to the OMP2 polypeptide is still unclear.
  • the OMP2 protein is chlamydia -specific, and does not seem to undergo any relevant antigenic variation, it can be considered probably the best marker of chlamydial infection in this study.
  • 2D maps were prepared as described above, starting from ]mg total EB protein per run, followed by blotting onto polyvinylidene difluoride membranes (BioRad PVDF membranes 20 ⁇ 20 cm, 0.2 micron pore size), as in reference 20.
  • the blots were stained with 0.1% (w/v) Coomassie Brilliant Blue R250 in 50% aqueous methanol for 5 minutes, and de-stained in 40% methanol, 10% acetic acid.
  • Membranes were dried at 37° C. and stored at ⁇ 20° C. for further analysis.
  • Selected protein spots were cut out and submitted to amino acid sequencing by Edman degradation using an automatic Protein/Peptide Sequencer (mod 470A; Applied Biosystem Inc.) connected on-line with a phenylthiohydantoin-amino acid analyser model 120A and a control/Data Module model 900A (Applied Biosystems Inc.). Typically 3 or 4 equivalent spots from similar blots were used, according to the estimated relative molar amount of protein in the spot.
  • the N-terminal sequences of spots 26, 31 and 33 do not match any database sequences, including the published serovar D sequence.
  • Table IV shows a summary of identifications (some putative) of several immunoreactive antigens, which were obtained either by comparison with previous 2D mapping data, or by homology searches with the N-terminal sequencing data obtained above.
  • This spot is believed to be the alpha chain of the C.trachomatis RNA polymerase (gi620029), based on its MW/pI position, and on its N-terminus sequence.
  • RNAP alpha chain has previously been described [23], it has never been reported as a chlamydial immunogen.
  • Four patients showed reactivity to this protein, demonstrating that it is immunogenic in humans as a consequence of chlamydial infection.
  • the intracellular parasitic nature of Chlamydia means that it can generally evade antibody-mediated immune responses
  • the antibody reactivity demonstrated above indicates that the immune system does encounter these proteins during natural infection, and the formation of antibodies may, for instance, also help to prime the T-cell-mediated immune responses.
  • Spots 18 and 46 appear to be homologous to the ompB gene in the serotype D genome, annotated as encoding a putative outer membrane protein.
  • the N-terminal sequences and pI & MW values are in agreement with the expected properties of an ompB gene product, after cleavage of the predicted N-terminal signal peptide.
  • spots 18 and 46 are present in a 2D electrophoretic map of a purified preparation of chlamydial outer membrane complex, which also supports the view that spots 18 and 46 represent the homologs of the serotype D ompB gene.
  • This spot is believed to be an aminopeptidase, based on its MW/pI position and on its N-terminus sequence (both in comparison with the published serovar D sequence pepA).
  • Four patients showed reactivity to this protein, demonstrating that it is immunogenic in humans as a consequence of chlamydial infection.
  • This spot is believed to be a GTP-binding protein, based on its MW/pI position and on its N-terminus sequence (both in comparison with the published serovar D sequence ychF). Two patients showed reactivity to this protein, demonstrating that it is immunogenic in humans as a consequence of chlamydial infection.
  • This spot is believed to be a stress-induced protease, based on its MW/pI position and on its N-terminus sequence (both in comparison with the published serovar D sequence htrA). Seven patients showed reactivity to this protein, demonstrating that it is immunogenic in humans as a consequence of chlamydial infection.
  • Cys and Trp are not determined in this type of analysis, and it is not possible to distinguish between Glu/Gin and Asp/Asn.
  • N-terminal residue is blocked due to some form of modification (eg. a lipoprotein).
  • Modification is often a characteristic of membrane-associated proteins in eukaryotes, but is also a characteristic of outer surface proteins or secreted proteins in bacterial species (eg. lipoproteins [24], mycoplasma outer membrane proteins [25], the FHA virulence factor of B.periussis [ 26] etc.).
  • CT-D gene refers to the gene name from refer- ence 2 and gives the names of genes likely to encode homologue proteins in C. trachomatis D. Theoretical pI/MW values in the last column, to be compared to the experimental values, were calculated the from CT-D gene sequences. Map Pre- loca- Anno- CT-D dicted spot tion N-terminal AA seq tation gene PI/MW 1 OMP2 — OMP2 omcB 7.65- clus- 7.92/ ter 54.5- 58.7 2 5.2- VA(D/K)NI(K/F)YNEE GroEL- groEL1 5.11/ 5.3/ (SEQ ID NO.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
US11/272,051 1998-12-18 2005-11-14 Chlamydia trachomatis antigens Abandoned US20060188516A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/272,051 US20060188516A1 (en) 1998-12-18 2005-11-14 Chlamydia trachomatis antigens
US12/586,601 US8114401B2 (en) 1998-12-18 2009-09-24 Chlamydia trachomatis antigens
US13/344,490 US20130156775A1 (en) 1998-12-18 2012-01-05 Chlamydia trachomatis antigens

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9828000.1A GB9828000D0 (en) 1998-12-18 1998-12-18 Antigens
GBGB9828000.1 1998-12-18
PCT/IB1999/002065 WO2000037494A2 (fr) 1998-12-18 1999-12-17 Antigenes a chlamydia trachomatis
US86829302A 2002-03-04 2002-03-04
US11/272,051 US20060188516A1 (en) 1998-12-18 2005-11-14 Chlamydia trachomatis antigens

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
PCT/IB1999/002065 Continuation WO2000037494A2 (fr) 1998-12-18 1999-12-17 Antigenes a chlamydia trachomatis
US09868293 Continuation 1999-12-17
US86829302A Continuation 1998-12-18 2002-03-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/586,601 Continuation US8114401B2 (en) 1998-12-18 2009-09-24 Chlamydia trachomatis antigens

Publications (1)

Publication Number Publication Date
US20060188516A1 true US20060188516A1 (en) 2006-08-24

Family

ID=10844562

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/272,051 Abandoned US20060188516A1 (en) 1998-12-18 2005-11-14 Chlamydia trachomatis antigens
US12/586,601 Expired - Fee Related US8114401B2 (en) 1998-12-18 2009-09-24 Chlamydia trachomatis antigens
US13/344,490 Abandoned US20130156775A1 (en) 1998-12-18 2012-01-05 Chlamydia trachomatis antigens

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/586,601 Expired - Fee Related US8114401B2 (en) 1998-12-18 2009-09-24 Chlamydia trachomatis antigens
US13/344,490 Abandoned US20130156775A1 (en) 1998-12-18 2012-01-05 Chlamydia trachomatis antigens

Country Status (12)

Country Link
US (3) US20060188516A1 (fr)
EP (3) EP1598362A3 (fr)
JP (2) JP2002534062A (fr)
AT (2) ATE371668T1 (fr)
CA (1) CA2355876A1 (fr)
CY (1) CY1107024T1 (fr)
DE (1) DE69937004T2 (fr)
DK (1) DK1140997T3 (fr)
ES (1) ES2292261T3 (fr)
GB (1) GB9828000D0 (fr)
PT (1) PT1140997E (fr)
WO (1) WO2000037494A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113637703A (zh) * 2021-08-06 2021-11-12 河北科技师范学院 一种布鲁氏菌L7/L12和GroES真核表达载体的构建方法及其应用

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
CA2340283A1 (fr) 1998-08-20 2000-03-02 Aventis Pasteur Limited Molecules d'acide nucleique codant la proteine pomp91a de chlamydia
CA2340330A1 (fr) 1998-08-20 2000-03-02 Aventis Pasteur Limited Molecules d'acide nucleique codant la proteine membrane d'inclusion c de chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
AU3790900A (en) 1998-12-01 2000-06-19 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
KR20090088972A (ko) 1998-12-08 2009-08-20 코릭사 코포레이션 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) * 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
AU774902B2 (en) 1998-12-28 2004-07-15 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
JP4832646B2 (ja) 1999-03-12 2011-12-07 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
EP1177301B1 (fr) 1999-05-03 2007-10-10 Sanofi Pasteur Limited Antigenes de chlamydia, fragments d'adn correspondants et utilisation de ceux-ci
EP1220925B8 (fr) 1999-09-20 2008-04-23 Sanofi Pasteur Limited Antigenes de chlamydia , fragments d'adn correspondants et utilisations
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
WO2001046224A2 (fr) 1999-12-22 2001-06-28 Aventis Pasteur Limited Antigenes anti-chlamydia, fragments d'adn correspondants et leurs utilisations
EP1278855B1 (fr) 2000-04-21 2008-03-12 Corixa Corporation Composes et procedes pour le traitement et le diagnostic d'une infection de chlamydia
DE60125350T2 (de) 2000-05-08 2007-07-12 Sanofi Pasteur Ltd., Toronto Chlamydia-antigene, entsprechende dns-fragmente und ihre verwendungen
US20040005667A1 (en) 2000-07-03 2004-01-08 Giuloi Ratti Immunisation against chlamydia pneumoniae
EP2189473A3 (fr) 2000-10-27 2010-08-11 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
EP2335724A1 (fr) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation contre la Chlamydia trachomatis
EP1531796B1 (fr) 2002-02-20 2016-09-28 GlaxoSmithKline Biologicals SA Microparticules comprenant des molecules adsorbees qui contiennent polypeptides
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
AU2003278166B2 (en) 2002-11-01 2009-01-29 Glaxosmithkline Biologicals S.A. Immunogenic composition
US7807802B2 (en) 2002-11-12 2010-10-05 Abbott Lab Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
DE60332477D1 (de) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2258365B1 (fr) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Utilisation de composés organiques pour potentialiser l'immunité
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
PT1631264E (pt) 2003-06-02 2009-11-03 Novartis Vaccines & Diagnostic Composições imunogénicas à base de micropartículas biodegradáveis que compreendem um toxóide de difteria e do tétano
WO2006002422A2 (fr) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Composes utilises pour l'immunopotentialisation
CA2571710A1 (fr) 2004-06-24 2006-11-02 Nicholas Valiante Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
JP2008508320A (ja) 2004-07-29 2008-03-21 カイロン コーポレイション Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
PL1858920T3 (pl) 2005-02-18 2016-12-30 Białka i kwasy nukleinowe z Escherichia coli związane z zapaleniem opon mózgowych/sepsą
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
US20110223197A1 (en) 2005-10-18 2011-09-15 Novartis Vaccines And Diagnostics Inc. Mucosal and Systemic Immunization with Alphavirus Replicon Particles
EP1969001A2 (fr) 2005-11-22 2008-09-17 Novartis Vaccines and Diagnostics, Inc. Antigènes de norovirus et de sapovirus
EP1976557A2 (fr) * 2005-12-22 2008-10-08 Novartis Vaccines and Diagnostics S.r.l. Antigenes chlamydia
US20090317421A1 (en) 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
EP2357184B1 (fr) 2006-03-23 2015-02-25 Novartis AG Composés d'imidazoquinoxaline en tant qu'immunomodulateurs
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
JP5653215B2 (ja) 2007-09-12 2015-01-14 ノバルティス アーゲー Ｇａｓ５７変異体抗原およびｇａｓ５７抗体
US8637053B2 (en) 2007-12-03 2014-01-28 President And Fellows Of Harvard College Chlamydia antigens
KR20160114196A (ko) 2007-12-21 2016-10-04 노파르티스 아게 스트렙토라이신 ｏ의 돌연변이 형태
US20110236489A1 (en) 2008-09-18 2011-09-29 Novartis Ag Vaccine adjuvant combinations
US11065323B2 (en) 2008-10-27 2021-07-20 Glaxosmithkline Biologicals Sa Purification method
AU2010203223B9 (en) 2009-01-05 2015-10-08 Epitogenesis Inc. Adjuvant compositions and methods of use
EP2385842A1 (fr) 2009-01-12 2011-11-16 Novartis AG Antigènes à domaines cna_b dans des vaccins contre des bactéries à gram positif
US8568732B2 (en) 2009-03-06 2013-10-29 Novartis Ag Chlamydia antigens
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
AU2010258677B2 (en) 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
WO2011008400A2 (fr) 2009-06-16 2011-01-20 Novartis Ag Dosages haut débit de bactéricides opsoniques et dépendant d'anticorps à médiation par le complément
WO2011026111A1 (fr) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Distribution par voie orale d'un vaccin au gros intestin pour induire une immunité mucosale
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
MX2012002723A (es) 2009-09-02 2012-04-11 Novartis Ag Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll.
EP2493510B1 (fr) 2009-09-30 2020-07-08 GlaxoSmithKline Biologicals SA Conjugaison de polysaccharides capsulaires de staphylococcus aureus de type 5 et de type 8
RS56000B1 (sr) 2009-10-30 2017-09-29 Glaxosmithkline Biologicals Sa Prečišćavanje stafilokokus aureus tip 5 i tip 8 kapsuliranih saharida
WO2011057148A1 (fr) 2009-11-05 2011-05-12 Irm Llc Composés et compositions permettant de moduler l'activité des tlr-7
CN102762206A (zh) 2009-12-15 2012-10-31 诺华有限公司 免疫增强化合物的均匀悬液及其用途
WO2011119759A1 (fr) 2010-03-23 2011-09-29 Irm Llc Composés (lipopeptides à base de cystéine) et compositions en tant qu'agonistes des tlr2 utilisés pour traiter des infections, inflammations, maladies respiratoires entre autres
EP2556377B1 (fr) 2010-04-08 2017-07-12 University of Pittsburgh - Of the Commonwealth System of Higher Education Analyse de cellules présentatrices d'antigène des lymphocytes b
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
WO2012031140A1 (fr) 2010-09-01 2012-03-08 Novartis Ag Adsorption d'immunopotentialisateurs en sels métalliques insolubles
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
EP2652511B8 (fr) 2010-12-14 2017-06-28 GlaxoSmithKline Biologicals SA Analyse de cytométrie en flux de matériau adsorbé à des sels métalliques
WO2012085668A2 (fr) 2010-12-24 2012-06-28 Novartis Ag Composés
EP2680885B8 (fr) 2011-03-02 2018-07-25 GlaxoSmithKline Biologicals SA Vaccins combinés comprenant des doses inférieures d'antigène et/ou d'adjuvant
CN103717235A (zh) 2011-06-24 2014-04-09 埃皮托吉尼西斯有限公司 作为抗原特异性免疫调节剂的包含选择的载体、维生素、单宁和类黄酮的组合的药物组合物
TR201909110T4 (tr) 2011-09-14 2019-07-22 Glaxosmithkline Biologicals Sa Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler.
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
JP6325986B2 (ja) 2012-03-07 2018-05-16 ノバルティス アーゲー 免疫学的に有用なアルギニン塩
EP2822581A2 (fr) 2012-03-08 2015-01-14 Novartis AG Formulation avec adjuvant de vaccins dtp de rappel
KR20150021933A (ko) 2012-05-22 2015-03-03 노파르티스 아게 수막염구균 혈청군 x 포합체
ES2670863T3 (es) 2013-02-01 2018-06-01 Glaxosmithkline Biologicals Sa Administración intradérmica de composiciones inmunológicas que comprenden agonistas del receptor de tipo Toll
EP3420355A1 (fr) 2016-02-22 2019-01-02 Boehringer Ingelheim Vetmedica GmbH Procédé d'immobilisation de biomolécules
EP3439704A1 (fr) 2016-04-05 2019-02-13 GSK Vaccines S.r.l. Compositions immunogènes
NL2019320B1 (en) * 2017-03-02 2018-09-21 Biosparq B V Diagnostic method and system for diagnosis
BR112020016314A2 (pt) 2018-02-12 2020-12-15 Inimmune Corporation Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular
WO2020086408A1 (fr) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bioprocédé d'expression génique transitoire basé sur une perfusion à haut rendement
CA3198876A1 (fr) 2020-11-04 2022-05-12 Eligo Bioscience Phages recombinants de cutibacterium acnes, leur procede de production et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1244706B (it) 1991-02-07 1994-08-08 Sclavo Spa Plasmide pctd isolato da chlamydia trachomatis serotipo d, suoi geni e proteine da essi codificate; plasmidi ricombinanti per l'espressionedi detti geni in sistemi eterologhi come proteine ricombinanti di fusione, preparazione di dette proteine ricombinanti e loro uso nella formulazione di vaccini e/o diagnostici
US5629167A (en) * 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
KR100735652B1 (ko) 1997-11-28 2007-07-06 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
US7041490B1 (en) * 1997-11-28 2006-05-09 Serono Genetics Institute, S.A. Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same
EP1073458A4 (fr) 1998-04-20 2005-01-12 Oregon State Proteines de chlamydia et leurs utilisations
EP1133572A4 (fr) 1998-11-12 2005-06-15 Univ California Sequence genomique de chlamydia pneumoniae
KR20090088972A (ko) 1998-12-08 2009-08-20 코릭사 코포레이션 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
EP1177301B1 (fr) 1999-05-03 2007-10-10 Sanofi Pasteur Limited Antigenes de chlamydia, fragments d'adn correspondants et utilisation de ceux-ci
EP1220925B8 (fr) 1999-09-20 2008-04-23 Sanofi Pasteur Limited Antigenes de chlamydia , fragments d'adn correspondants et utilisations
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
WO2001046224A2 (fr) 1999-12-22 2001-06-28 Aventis Pasteur Limited Antigenes anti-chlamydia, fragments d'adn correspondants et leurs utilisations
EP1278855B1 (fr) 2000-04-21 2008-03-12 Corixa Corporation Composes et procedes pour le traitement et le diagnostic d'une infection de chlamydia
DE60125350T2 (de) 2000-05-08 2007-07-12 Sanofi Pasteur Ltd., Toronto Chlamydia-antigene, entsprechende dns-fragmente und ihre verwendungen
US20040005667A1 (en) 2000-07-03 2004-01-08 Giuloi Ratti Immunisation against chlamydia pneumoniae
JP2004534526A (ja) 2001-04-09 2004-11-18 ショー、アラン、クリスチァン 細胞内細菌からのタンパク質を同定する方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113637703A (zh) * 2021-08-06 2021-11-12 河北科技师范学院 一种布鲁氏菌L7/L12和GroES真核表达载体的构建方法及其应用

Also Published As

Publication number Publication date
EP1598362A3 (fr) 2006-03-22
ES2292261T3 (es) 2008-03-01
EP1857464A2 (fr) 2007-11-21
DK1140997T3 (da) 2007-12-27
US20130156775A1 (en) 2013-06-20
PT1140997E (pt) 2007-12-10
JP2010220622A (ja) 2010-10-07
ATE371668T1 (de) 2007-09-15
DE69937004T2 (de) 2008-05-21
EP1857464A3 (fr) 2008-04-02
WO2000037494A2 (fr) 2000-06-29
CA2355876A1 (fr) 2000-06-29
DE69937004D1 (de) 2007-10-11
EP1598362A2 (fr) 2005-11-23
CY1107024T1 (el) 2012-09-26
JP2002534062A (ja) 2002-10-15
WO2000037494A3 (fr) 2000-10-12
US20100098697A1 (en) 2010-04-22
EP1140997B1 (fr) 2007-08-29
US8114401B2 (en) 2012-02-14
EP1857464B1 (fr) 2011-07-13
ATE516299T1 (de) 2011-07-15
EP1140997A2 (fr) 2001-10-10
GB9828000D0 (en) 1999-02-10

Similar Documents

Publication Publication Date Title
US8114401B2 (en) Chlamydia trachomatis antigens
Sanchez‐Campillo et al. Identification of immunoreactive proteins of Chlamydia trachomatis by Western blot analysis of a two‐dimensional electrophoresis map with patient sera
Bannantine et al. A secondary structure motif predictive of protein localization to the chlamydial inclusion membrane
Stephens et al. High-resolution mapping of serovar-specific and common antigenic determinants of the major outer membrane protein of Chlamydia trachomatis.
EP0629132B1 (fr) Toxine vacuolisante purifiee issue de helicobacter pylori et methodes d'utilisation de cette toxine
EP2342215A1 (fr) Méthodes et compositions pour antigènes de chlamydia utilisées dans le diagnostic et le traitement de maladies et d'infections à chlamydia
Noordhoek et al. A new attempt to distinguish serologically the subspecies of Treponema pallidum causing syphilis and yaws
Su et al. Immunogenicity of a synthetic oligopeptide corresponding to antigenically common T-helper and B-cell neutralizing epitopes of the major outer membrane protein of Chlamydia trachomatis
US7807810B2 (en) Nucleic acids encoding the major outer membrane protein of the causative agent of human granulocytic ehrlichiosis and peptides encoded thereby
US5071962A (en) Nucleotide, deduced amino acid sequence, isolation and purification of heat-shock chlamydial proteins
CA2683888A1 (fr) Antigenes de type chlamydia comme reactifs pour le diagnostic et le traitement d'infection et de maladie a chlamydia
US7169393B2 (en) Antigenic peptide fragments of VapA protein, and uses thereof
Fan et al. Antigen conformation dependence of Chlamydia trachomatis infectivity neutralization
CA2190359C (fr) Acides nucleiques de rochalimaea henselae et de rochalimaea quintana et procedes et composition pour le diagnostic de l'infection par rochalimaea henselae et rochalimaea quintana
WO1999052370A1 (fr) Acides nucleiques codant une proteine de membrane exterieure d'agent d'ehrlichiose granulocytaire humaine
US6436399B1 (en) Nucleic acid encoding the major outer membrane protein of the causative agent of human granulocytic ehrlichiosis and peptides encoded thereby
Larsen et al. The humoral immune response to Chlamydia trachomatis in patients with acute reactive arthritis
Birkelund et al. Characterization of two conformational epitopes of the Chlamydia trachomatis serovar L2 DnaK immunogen
Cheng et al. Characterization of the humoral response induced by a peptide corresponding to variable domain IV of the major outer membrane protein of Chlamydia trachomatis serovar E
US20020012919A1 (en) Nucleic acids of rochalimaea henselae and methods and compositions for diagnosing rochalimaea henselae and rochalimaea quintana infection
JP2001286295A (ja) クラミジア・トラコマチス検出用抗体
Ts' ao et al. Monoclonal antibody to a major outer membrane protein of feline Chlamydia psittaci: antibody specificity and anti-idiotype antibody production
Villeneuve et al. Determination of neutralizing epitopes in variable domains I and IV of the major outer-membrane protein f rom Chlamydia trachomatis serovar K
Christiansen et al. Molecular biology and serodiagnostics of Chlamydia pneumoniae—potential way to a vaccine
AU2001252038A1 (en) Antigenic peptide fragments of VapA protein, and uses thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION